SCHEDULE: PFM Health Sciences Amends Werewolf Therapeutics Stake
Beneficial Ownership Report
PFM Health Sciences and its affiliates have filed an amendment to their Schedule 13G, reporting a 0.9% beneficial ownership stake in Werewolf Therapeutics, Inc.
Summary
- PFM Health Sciences, LP, PFM Health Sciences GP, LLC, Partner Asset Management, LLC, and Brian D. Grossman (collectively, the "Reporting Persons") have filed an Amendment No. 4 to Schedule 13G.
- The filing reports beneficial ownership of 401,110 shares of common stock in Werewolf Therapeutics, Inc.
- This represents 0.9% of Werewolf Therapeutics, Inc.'s outstanding shares.
- The percentage is based on 44,873,646 shares outstanding as of May 2, 2025, as reported in the issuer's Form 10-Q filed on May 8, 2025.
- The Reporting Persons share voting and dispositive power over all 401,110 shares.
- The shares were not acquired for the purpose of changing or influencing the control of Werewolf Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The filing is a routine compliance update regarding beneficial ownership and does not contain information that would significantly alter the perception of the company's financial health or strategic direction. The reported stake is small (0.9%) and explicitly not for control purposes, indicating a neutral impact.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership by an investment firm in a biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact that an investment firm maintains a small stake in a company within the sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding the ownership structure and confirms a minor, non-controlling stake held by PFM Health Sciences and its affiliates.
Key Dates
| Date | Description |
|---|---|
| 2024-02-01 | Date of power of attorney for Brian Grossman, incorporated by reference. |
| 2024-02-14 | Date power of attorney was filed as an attachment to a Schedule 13G/A for Praxis Precision Medicines, Inc. |
| 2025-05-02 | Date as of which Werewolf Therapeutics, Inc. reported 44,873,646 shares outstanding in its Form 10-Q. |
| 2025-05-08 | Date Werewolf Therapeutics, Inc. filed its Form 10-Q with the SEC. |
| 2025-06-30 | Date of event which requires filing of this statement (reporting period end). |
| 2025-08-14 | Date of filing of this Schedule 13G Amendment No. 4. |
Keywords
Werewolf Therapeutics, PFM Health Sciences, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.